Altered IL-6 signalling and risk of tuberculosis: a multi-ancestry mendelian randomisation study

This publication has 54 references indexed in Scilit:

• The effect of interleukin-6 signaling on severe malaria: A Mendelian randomization analysis
  International Journal of Infectious Diseases, 2023
• Multi-ancestry Mendelian randomization of omics traits revealing drug targets of COVID-19 severity
  EBioMedicine, 2022
• Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
  JAMA, 2021
• IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial
  The Lancet, 2021
• Locally-secreted interleukin-6 is related with radiological severity in smear-negative pulmonary tuberculosis
  Cytokine, 2020
• ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors)
  Clinical Microbiology and Infection, 2018
• A Locus at 5q33.3 Confers Resistance to Tuberculosis in Highly Susceptible Individuals
  The American Journal of Human Genetics, 2016
• The role of ancestry in TB susceptibility of an admixed South African population
  Tuberculosis, 2014
• Therapeutic targeting of interleukin-6 trans-signaling does not affect the outcome of experimental tuberculosis
  Immunobiology, 2012
• The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis
  The Lancet, 2012